This study investigates the potential involvement of mutations in the IL-36 receptor antagonist (IL36RN, IL-36RA) in the pathogenesis of Crohn’s disease and evaluates the IL-36 signaling pathway as a drug target for IL36RN-mutated patients. Here, IL36RN is linked to Crohn disease.